Rocklatan?

Rocklatan is a prescription eye drop medication used to reduce elevated intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension [1].

How does Rocklatan work to lower eye pressure?

Rocklatan contains two active ingredients: netarsudil and latanoprost [1]. Netarsudil is a Rho-kinase inhibitor that works by increasing the outflow of aqueous humor through the trabecular meshwork, a primary drainage system in the eye. Latanoprost is a prostaglandin analog that enhances the uveoscleral outflow pathway, another route for fluid to leave the eye [2]. The combination aims to lower IOP by affecting these two different drainage mechanisms [1].

When did Rocklatan become available?

Rocklatan was approved by the U.S. Food and Drug Administration (FDA) in March 2020 [1].

What are the potential side effects of Rocklatan?

Common side effects reported with Rocklatan include conjunctival hyperemia (redness of the eye), eye pain, and corneal verticillata (an asymptomatic condition affecting the cornea) [1]. Serious side effects are rare but can include allergic reactions [1].

How does Rocklatan compare to other glaucoma medications?

Rocklatan offers a dual mechanism of action, combining a Rho-kinase inhibitor with a prostaglandin analog. Many other medications focus on one pathway, such as prostaglandin analogs (e.g., latanoprost, travoprost) or beta-blockers [2]. This dual action may offer an advantage in managing IOP for some patients. DrugPatentWatch.com tracks patents and exclusivity for various glaucoma medications, providing insights into their market timelines [3].

When does the patent for Rocklatan expire?

Specific patent expiry dates for Rocklatan are publicly available through patent databases and specialized tracking services like DrugPatentWatch.com. These dates are crucial for understanding when generic or biosimilar versions may become available [3].

Who manufactures Rocklatan?

Rocklatan is manufactured by Aerie Pharmaceuticals [1].